Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyradiotherapyDiseaseColon CancerRectal CancerSubgroupMismatch Repair - deficient / Microsatellite Instability - high (dMMR/MSI-H)ICD10C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C20MeSHColonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsSequenceAtezoTRIBE: FOLFOXIRI (IRIN165/OXAL85/CFOL200/FU3200)/ATEZ840/BEVA5, colorect. Ca (PID2672) -|- FOLFOXIRI (IRIN165/OXAL85/CFOL200/FU3200)/ATEZ840/BEVA5 - ATEZ840/BEVA5/CFOL200/FU3200, colorect. (PID2673)CAO/ARO/AIO-04CAO/ARO/AIO-12, Arm ACAO/ARO/AIO-12, Arm BFOLFIRINOX (OXAL85/CFOL400/IRIN180/FU2400), Rectal Ca, neoadj., A (PID2049) -|- B (PID2050) -|- C (PID2051)FOLFIRINOX (OXAL85/CFOL400/IRIN180/FU2400), Rectal Ca, neoadj., A (PID2049) -|- B (PID2050) -|- C (PID2052)FU1000/Radiation, Rectal Ca, neoadj./adj. (PID464) -|- FU500, adj. (PID465)PROSPECT: FOLFOX groupRectal Ca adjuvant (Capecitabine/Radiation)Rectal Ca neoadjuvant/adjuvant (Capecitabine/Radiation)ChemotherapyChemo-substanceAtezolizumabBevacizumabCapecitabineDostarlimabFluorouracilFolinic acidIrinotecanOxaliplatinChemo-substanceAtezolizumabBevacizumabCapecitabineDostarlimabFluorouracilFolinic acidIrinotecanOxaliplatinChemo-substanceAtezolizumabBevacizumabCapecitabineDostarlimabFluorouracilFolinic acidIrinotecanOxaliplatinChemo-substanceAtezolizumabBevacizumabCapecitabineDostarlimabFluorouracilFolinic acidIrinotecanOxaliplatinNo. Substances12346 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimNo. Substances1234Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseInductionMaintenanceneoadjuvantneoadjuvant / adjuvantseveral possibleTherapy intentioncurativepalliativeRisksAllergic ReactionAnemia Hb below 8g/dlAstheniaBleedingCardiotoxicityConstipationDepressionDiarrheaDysphagiaDyspneaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHand-Foot SyndromeHypertensionHypothyroidismIncrease AminotransferasesInfectionsMucositisNauseaNeuropathyNeurotoxicityNeutropeniaPainProteinuriaPruritusPyrexiaRadiation DermatitisRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAntoniotti C Bahadoer RRCercek A Conroy THofheinz RDRödel CSauer RSchrag DSerra-Aracil XDiseaseMet. kolorektales Karzinom, Erstlinie, ECOG 0-2, über 70 Jahre nur bei ECOG 0Rektum-Ca, cT2N+, cT3N+/-, cM0, ECOG 0-2Rektum-Ca, cT3 oder cT4, M0, ECOG 0-1Rektum-Ca, cT4a oder cT4b, cN2, ECOG 0-1Rektum-Ca, resektabel (exklusive Std. I ), Patienten unter 75Rektum-Ca, Stadium cT2-T3a/b, cN0, cM0Rektum-Ca adj.: nach TME oder PME mit R0 Resektion, neoadjuvant prä-OP; ECOG 0-1Rektumkarzinom, nicht weiter als 12 cm, neoadj./adj., ECOG 0-2Rektumkarzinom, Stadium II/III, dMMR/MSI-HOriginDepartment of Surgery, Leiden University Medical Center, Leiden, Netherlands, RAPIDO trialDivision of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, USAGerman Rectal Cancer Study Group, CAO/ARO/AIO-04Institut de Cancerologie de Lorraine and APEMAC, Universite de Lorraine, Nancy, France, UNICANCER-PRODIGE 23 trialInterdisziplinäres Tumorzentrum Mannheim und die Med. Klinik III, Universitätsklinik Mannheim, DeutschlandMemorial Sloan Kettering Cancer Center, New York, PROSPECT trialThe German Rectal Cancer Study Group, CAO/ARO/AIO-94 StudieUniversitat Autonoma de Barcelona, Barcelona, Spain, TAU-TEM studyUniversity Hospital of Pisa, Pisa, Italy, AtezoTRIBE trialProtocols in Revision 17 protocols foundProtocols under revision.Capecitabine 1000 / Oxaliplatin 130, Rectal Cancer, neoadjuvant (PID2054 V1.1)Capecitabine 1250, Rectal Cancer, adjuvant, part C (PID2052 V1.1)Capecitabine 1250, Rectal Cancer, neo-/adjuvant, Part B (PID422 V1.2)Capecitabine 800 / Radiation, Rectal Cancer, neoadjuvant, part B (PID2050 V1.0)Capecitabine 825 / Radiation, Rectal Cancer, Neo/Adjuvant, Part A (PID421 V1.2)Capecitabine 825 / Radiation, Rectal Cancer, neoadjuvant (PID2265 V1.0)Dostarlimab 500, Rectal Cancer (PID2238 V1.0)Fluorouracil 1000 / Radiation, Rectal Cancer, neoadjuvant/adjuvant (PID464 V1.2)Fluorouracil 500, Rectal Cancer, adjuvant (PID465 V1.2)FOLFIRINOX - Oxaliplatin 85 / Folinic Acid 400 / Irinotecan 180 / Fluorouracil 2400, Rectal Cancer, neoadjuvant, part A (PID2049 V1.1)FOLFOX-4 - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Rectal Cancer, neoadjuvant (PID2055 V1.0)FOLFOXIRI - Irinotecan 165 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 3200 / Atezolizumab 840 / Bevacizumab 5 - Atezolizumab 840 / Bevacizumab 5 / Folinic Acid 200 / Fluorouracil 3200, Colorectal Carcinoma, Maintenance (PID2673 V1.0)FOLFOXIRI - Irinotecan 165 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 3200 / Atezolizumab 840 / Bevacizumab 5, Colorectal Carcinoma (PID2672 V1.0)Modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Rectal Cancer, adjuvant, part C (PID2051 V1.0)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Rectal Cancer, neoadjuvant / adjuvant (PID2379 V1.0)Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 2400, Rectal Cancer, adjuvant, B (PID64 V1.0)Oxaliplatin 50 / Fluorouracil 250 / Radiation, Rectal Cancer, neoadjuvant, Part A (PID65 V1.0)
